Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3 -ITD-Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial

David Martinez-Cuadron, Rebeca Rodriguez-Veiga, Juan Miguel Bergua Burgues, Jesús Lorenzo Algarra, Carmen Botella, Jose Antonio Pérez-Simón, Teresa Bernal Del Castillo, Mar Tormo, Maria Calbacho, Olga Salamero, Josefina Serrano, Victor Noriega Concepcion, Juan Antonio Lopez Lopez, Susana Vives, Jose Luis Lopez Lorenzo, Mercedes Colorado, Maria Vidriales Vicente, Raimundo Garcia Boyero, Maria Teresa Olave Rubio, Pilar Herrera, Olga Arce, Manuel Barrios Garcia, Maria Jose Sayas Lloris, Marta Polo, Maria Isabel Gómez Roncero, Eva Barragán, Rosa Ayala, Carmen Chillon, Maria Jose Calasanz, Bruno Paiva, Blanca Boluda, Ignacio Casas Aviles, Pilar Lloret Madrid, Claudia Sargas, María-José Sánchez-Sánchez, Carlos Rodríguez-Medina, Laida Cuevas Palomares, Júlia Morán Sánchez, M Carmen Mateos Rodríguez, Matxalen Olivares Salaverri, Maria Del Carmen Martinez Chamorro, Natalia Alonso Vence, Sandra Suarez Ordonez, Irene Sanchez Vadillo, María Solé-Rodríguez, Bernardo Javier González González, Antonio Martinez Frances, Rebeca Cuello, Alfonso Fernández Fernández, Jorge Labrador, Pau Montesinos

Blood (2024) 144 (Supplement 1): 2895.

https://doi.org/10.1182/blood-2024-205064

Published: 2024

Journal Articles

A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Blood (2024) 144 (Supplement 1): 4986.

https://doi.org/10.1182/blood-2024-201407

Published: 2024

Journal Articles

Enhanced Validation of the FLT3 -like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial

Blood (2024) 144 (Supplement 1): 1552.

https://doi.org/10.1182/blood-2024-201264

Published: 2024

Journal Articles

Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3 -ITD Negative AML

Pau Montesinos, Rebeca Rodriguez-Veiga, Juan Miguel Bergua Burgues, Jesús Lorenzo Algarra, Carmen Botella, Eduardo Rodriguez Arboli, Teresa Bernal Del Castillo, Mar Tormo, Maria Calbacho, Olga Salamero, Josefina Serrano, Victor Noriega Concepcion, Juan Antonio Lopez Lopez, Susana Vives, Jose Luis Lopez Lorenzo, Mercedes Colorado, Maria Vidriales Vicente, Raimundo Garcia Boyero, Maria Teresa Olave Rubio, Pilar Herrera, Olga Arce, Manuel Barrios Garcia, Maria Jose Sayas Lloris, Marta Polo, Maria Isabel Gómez Roncero, Eva Barragán, Rosa Ayala, Carmen Chillon, Maria Jose Calasanz, Bruno Paiva, Blanca Boluda, Ignacio Casas Aviles, Pilar Lloret Madrid, María-José Sánchez-Sánchez, Carlos Rodríguez-Medina, Laida Cuevas Palomares, Jose Ángel Raposo Puglia, M Carmen Mateos Rodríguez, Matxalen Olivares Salaverri, Maria Del Carmen Martinez Chamorro, Natalia Alonso Vence, Sandra Suarez Ordoñez, Irene Sanchez Vadillo, María Solé-Rodríguez, Bernardo Javier González González, Antonio Martinez Frances, Rebeca Cuello, Alfonso Fernández Fernández, David Martinez-Cuadron, Jorge Labrador

Blood (2024) 144 (Supplement 1): 1512.

https://doi.org/10.1182/blood-2024-204779

Published: 2024

Journal Articles

Molecular Mechanisms of Quizartinib Response in FLT3-ITD Negative AML: An Updated Analysis from the Pethema Quiwi Trial

Blood (2024) 144 (Supplement 1): 6135.

https://doi.org/10.1182/blood-2024-201316

Published: 2024

Journal Articles

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Blood (2023) 142 (Supplement 1): 974.

https://doi.org/10.1182/blood-2023-180482

Published: 2023

Journal Articles

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Blood (2023) 142 (Supplement 1): 6037.

https://doi.org/10.1182/blood-2023-180710

Published: 2023

Journal Articles

High Correlation Clinical Responses to 1 st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test

Pau Montesinos, MD, Joan Ballesteros, David Martínez-Cuadrón, Joaquín Martínez-López, Josefina Serrano, Jaime Perez de Oteyza, Pascual Fernández, Gabriela Rodriguez-Macías, Mª Belén Vidriales, Pilar Herrera, MD PhD, Mar Tormo, MD PhD, Juan Bergua, Raimundo García, MD, Susana Vives, Mª Ángeles Fernández, Esperanza Lavilla, MD, Santiago Jimenez, Jose Antonio Pérez-Simón, Adriana Simiele, Ataulfo González, Bernardo J. González, Carmen Burgaleta, Juan Antonio López, Concepción Bethancourt, Guiomar Bautista, Arancha Alonso, Mercedes Colorado, Jordi Sierra, Begoña Navas, José Angel Hernández-Rivas, Juan Antonio Vera, Mª Lourdes Amador, Raúl Cordoba, MD, Adolfo de la Fuente, Fernando Ramos, MD PhD MPH, Carlos Javier Cerveró, Consolación Rayón, Olga Salamero, Edelmira Martí, Aurelio López, Teresa Olavé, Marta Gaspar, Julian Gorrochategui, José Luis Rojas, Cristina Gomez, Pilar Hernández, Alicia Robles, Ignacio Ortega, Jesús Villoria, Federico Moscardó, Iñaki Troconiz, Miguel A. Sanz, MD PhD

Blood (2015) 126 (23): 4837.

https://doi.org/10.1182/blood.V126.23.4837.4837

Published: 2015

Journal Articles

Pharmacological Profile Of Cytarabine and Idarubicin In Patient Samples (ex vivo) With Newly Diagnosed Acute Myeloid Leukemia Identifies Responders Vs Non Responders

Blood (2013) 122 (21): 3923.

https://doi.org/10.1182/blood.V122.21.3923.3923

Published: 2013

Journal Articles

Population Pharmacological Profiles Of AML Treatments In Patient Samples By Automated Flow Cytometry; A Bridge To Individualized Medicine

Blood (2013) 122 (21): 1347.

https://doi.org/10.1182/blood.V122.21.1347.1347

Published: 2013

Journal Articles

Personalizing Therapies With Ex Vivo Pharmacological Responses May Uncover The Differences Between IDA-DNR-MIT Among European AML Protocols

Blood (2013) 122 (21): 1294.

https://doi.org/10.1182/blood.V122.21.1294.1294

Published: 2013

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3 -ITD-Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial

A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Enhanced Validation of the FLT3 -like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial

Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3 -ITD Negative AML

Molecular Mechanisms of Quizartinib Response in FLT3-ITD Negative AML: An Updated Analysis from the Pethema Quiwi Trial

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

High Correlation Clinical Responses to 1 st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test

Pharmacological Profile Of Cytarabine and Idarubicin In Patient Samples (ex vivo) With Newly Diagnosed Acute Myeloid Leukemia Identifies Responders Vs Non Responders

Population Pharmacological Profiles Of AML Treatments In Patient Samples By Automated Flow Cytometry; A Bridge To Individualized Medicine

Personalizing Therapies With Ex Vivo Pharmacological Responses May Uncover The Differences Between IDA-DNR-MIT Among European AML Protocols

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only